SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
The Company entered into Subscription Agreements with three related persons (the Acting CEO, CFO, and an Executive Director) to purchase US$1,200,000 of common stock in two tranches under Regulation S, representing approximately 2,666,666 shares at $0.45 per share. This private placement of restricted securities to insiders is a material dilutive issuance subject to Rule 144 and Regulation S resale limitations.
View raw filing on EDGAR →American Airlines exercised subscription warrants to acquire 31,838,775 common shares, resulting in a total capital increase of BRL 512,811,716.28 and bringing total outstanding shares to 400,829,250. This represents a material dilutive issuance of equity securities. While the warrants were previously issued (not a new private placement), the exercise event itself constitutes a material capital-raising transaction that dilutes existing shareholders and would affect investor assessment of ownership and voting power.
View raw filing on EDGAR →The filing discloses a private placement financing completed on October 15, 2026, in which PURE Bioscience issued 10,183,486 shares of common stock at $0.0545 per share to accredited investors, raising $555,000. The shares were issued pursuant to a Securities Purchase Agreement under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D—a classic unregistered equity issuance. Item 3.02 explicitly incorporates the private placement details, confirming this is an unregistered sale of equity securities. The substantial share count and dilutive nature of the issuance make this material to investors assessing the registrant's capital structure and ownership.
View raw filing on EDGAR →The filing discloses completion of a private placement of 20,338,974 shares of common stock for approximately $24.0 million in gross proceeds. This is an unregistered equity issuance that materially dilutes existing shareholders and represents a significant capital raise for the company, meeting the definition of dilutive_issuance.
View raw filing on EDGAR →Clean Energy Technologies issued a $500,000 convertible promissory note to Falcon Venture Limited on October 18, 2026, with conversion rights into common stock at 85% of the lowest traded price during the ten trading days prior to conversion. The filing explicitly discloses this under Item 3.02 (Unregistered Sales of Equity Securities) and Item 1.01 (Material Definitive Agreement), indicating a dilutive equity issuance. The conversion feature and the specific cap on conversion shares (2,432,004 shares) underscore the dilutive nature of this transaction, which is material to investors assessing capital structure and ownership dilution.
View raw filing on EDGAR →Nu-Med Plus entered into Subscription Agreements with accredited investors to sell 171,232 shares of Series A Preferred Stock for $450,000, and issued 50,000 shares of Series A Preferred Stock to a consultant, pursuant to Section 4(a)(2) and Regulation D exemptions. Upon full conversion, these securities would result in the issuance of approximately 4.4 million shares of common stock, materially diluting existing shareholders.
View raw filing on EDGAR →LanzaTech issued FSI Warrants in an unregistered transaction relying on Section 4(a)(2) of the Securities Act, with additional warrants to be issued on a future closing date, resulting in dilutive equity upon exercise.
View raw filing on EDGAR →Monroe Capital Income Plus Corp completed an unregistered private placement of 839,725 shares of common stock at $9.70 per share for aggregate proceeds of $8.1 million, pursuant to subscription agreements and exempt under Section 4(a)(2) and Regulation D/S.
View raw filing on EDGAR →Blue Owl Real Estate Net Lease Trust sold 2,883,572 Class I common shares for approximately $31.0 million to feeder vehicles in an unregistered offering exempt under Section 4(a)(2), Regulation D, and/or Regulation S.
View raw filing on EDGAR →North Haven Net REIT disclosed unregistered sales of multiple classes of equity securities (Class I, Class F-I, Class E, and Class L-I shares) totaling approximately $9.2 million in aggregate consideration as of October 1, 2026. The sales were exempt from registration under Section 4(a)(2) and Regulation D Rule 506, which are hallmarks of private placements. This is a material dilutive issuance typical of REIT capital raises and directly fits Item 3.02 disclosure requirements.
View raw filing on EDGAR →Blue Owl Digital Infrastructure Trust sold 900,630 common shares for approximately $9.6 million in gross proceeds on October 1, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions from Securities Act registration.
View raw filing on EDGAR →Dogwood Therapeutics entered into a Subscription Agreement to issue 4,098,360 shares of common stock at $1.22 per share in a private placement with Sealbond (a subsidiary of CK Life Sciences), raising approximately $5 million. The unregistered shares are sold under Section 4(a)(2) of the Securities Act and Regulation D, materially diluting existing shareholders' ownership and representing a significant capital raise for the development-stage biopharmaceutical company.
View raw filing on EDGAR →Curis entered into a Securities Purchase Agreement on October 16, 2026, for the sale of 16,666,680 shares of common stock (or pre-funded warrants) plus common warrants to purchase an additional 16,666,680 shares at an effective combined price of $0.51 per share, generating approximately $8.5 million in gross proceeds. The unregistered securities were sold to institutional accredited investors and qualified institutional buyers pursuant to Section 4(a)(2) exemption, and the company also amended existing warrants to reduce their exercise price.
View raw filing on EDGAR →ConnectM Technology Solutions conducted an unregistered sale of equity securities embedded in the convertible Note Two-B under Section 4(a)(2) and Regulation D Rule 506 to an accredited investor, representing a private placement with dilutive conversion rights.
View raw filing on EDGAR →Rubico announced a registered direct offering of $8.5 million in senior convertible notes and warrants to a single institutional investor. The offering includes convertible notes with a 12-month maturity, warrants exercisable for 25,903,577 common shares at $0.3646 per share, and commitment shares of 1,295,179 shares. This is a dilutive equity issuance raising capital through convertible securities and warrants, which would significantly dilute existing shareholders and is material to investors assessing the company's capital structure and ownership.
View raw filing on EDGAR →TCGX completed a $160 million PIPE (Private Investment in Public Equity) financing at $10.00 per share from multiple healthcare investors including Viking Global Investors, ADAR1 Capital Management, BVF Partners, Samsara BioCapital, and Vianti Capital, in connection with the TriGemX Bio business combination.
View raw filing on EDGAR →The Sponsor completed an unregistered private placement of 450,000 Class A ordinary shares at $10.00 per share ($4.5 million aggregate) simultaneously with the IPO closing, exempted from registration under Section 4(a)(2) of the Securities Act.
View raw filing on EDGAR →BioAtla entered into a new Standby Equity Purchase Agreement (SEPA) with Yorkville granting the right to sell up to $40 million of common stock over 36 months at 97% of the lowest daily VWAP, and issued 182,110 warrant shares as a commitment fee. The company simultaneously terminated its prior SEPA with Yorkville ($15 million facility), replacing it with this larger dilutive equity financing arrangement that provides on-demand capital access.
View raw filing on EDGAR →OS Therapies completed the initial closing of a warrant exercise inducement and exchange offer on October 15, 2026, generating $7.2 million in gross proceeds from accredited investors. The Company issued 5,517,253 new common stock purchase warrants at $1.40 per share in exchange for the exercise or pre-funding of existing warrants at a reduced exercise price of $1.30 per share, with potential total proceeds of $12.3 million if all existing warrants are exercised. The securities were offered in reliance on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D and have not been registered under the Securities Act.
View raw filing on EDGAR →The filing discloses unregistered sales of equity securities under Item 3.02, specifically "Waiver Pre-Funded Warrants and the Waiver Pre-Funded Warrant Shares" offered and sold in reliance on Section 4(a)(2) and Rule 506(b) exemptions. This is a classic private placement of dilutive securities. While Item 2.03 references a promissory note advance from the CSO, the primary material event disclosed is the unregistered equity issuance, which would materially affect a reasonable investor's assessment of share dilution and capital structure.
View raw filing on EDGAR →The Company elected to satisfy milestone payments under the consultancy agreement through issuance of unregistered shares to the consultant, calculated by dividing the milestone payment by the last closing stock price, with a six-month holding period and Rule 144 restrictions.
View raw filing on EDGAR →The filing discloses an unregistered sale of 6,529,494 restricted shares of common stock to Mandragola Ltd. issued via cashless exercises of warrants between October 13-19, 2026. The shares were issued under Section 4(a)(2) exemption and represent a dilutive issuance that increased outstanding shares to 20,663,177. This is a material capital event typical of warrant exercises and dilutive equity issuances that would affect investor assessment of ownership and equity value.
View raw filing on EDGAR →Nexpu Ltd. completed an unregistered private placement of 40,000,000 units (each consisting of one Class A ordinary share and one warrant to purchase ordinary shares at $0.71 per share) at $0.70 per unit for aggregate gross proceeds of up to $28,000,000, relying on Section 4(a)(2) of the Securities Act and Regulation S exemptions to non-US persons. The issuance includes both the ordinary shares and warrants, representing a material dilutive capital-raising transaction.
View raw filing on EDGAR →Chilwa announced the partial exercise of an over-allotment option by Maxim Group LLC, resulting in the issuance of 568,340 ordinary shares (via 56,834 ADSs) at US$5.59 per ADS, generating US$317,702 in gross proceeds. This is a dilutive equity issuance that increases the share count and raises capital, typical of post-IPO over-allotment exercises. The announcement explicitly states the number of shares issued and the proceeds, and notes that total US offering proceeds now stand at approximately US$3.82 million, making this a material capital-raising event for the recently listed company.
View raw filing on EDGAR →The filing discloses unregistered sales of equity securities under Item 3.02, including 565,000 units (shares and warrants) sold to Investments AKA and accredited investors for $1,825,000 aggregate proceeds. The convertible note conversion and private placement represent dilutive equity issuances claimed exempt under Section 4(a)(2) and Regulation D, materially increasing share count from the current base to 13,711,824 shares outstanding post-issuance.
View raw filing on EDGAR →The exhibit announces exchange of all outstanding Series A4 Preferred Shares (1,666,837 shares) and 3,190,000 Series C Preferred Shares for rights to receive ordinary shares, plus full exercise of remaining 2023 warrant warrants. While technically an exchange rather than a new issuance, the net effect is conversion of preferred securities and warrants into ordinary shares (6,435,332 post-split ordinary shares), which dilutes existing shareholders. The company explicitly states this removes "a meaningful overhang on our Ordinary Shares," indicating material dilutive impact. The capital structure simplification is material to investors assessing ownership and equity value.
View raw filing on EDGAR →The filing discloses unregistered issuance of 922,188 shares of common stock on October 15, 2026, including 101,549 shares to CEO David Palach, 51,000 to CFO Lital Barda, 208,639 to directors, 51,000 to a consultant, and 510,000 to other consultants, all exempt under Section 4(a)(2). This is a material dilutive equity issuance typical of small-cap companies raising capital or compensating service providers through unregistered private placements.
View raw filing on EDGAR →The filing discloses an unregistered issuance of new warrants to purchase 406,198 shares of common stock in reliance on Section 4(a)(2) of the Securities Act. Item 3.02 explicitly confirms this is an unregistered sale of equity securities. The warrants are issued as consideration for a waiver of restrictive covenants in a prior securities purchase agreement, representing a dilutive capital transaction typical of private placements at small-cap issuers.
View raw filing on EDGAR →Eva Live Inc. disclosed entry into an Equity Purchase Agreement with Hudson Global Ventures granting the Company the right to direct the Investor to purchase up to 5,000,000 shares of common stock for up to $10,000,000, plus issuance of a warrant to purchase 275,000 additional shares at $0.01 per share. The securities were registered under a shelf registration statement (Form S-3), indicating a registered direct offering structure typical of dilutive equity issuances. This represents a material capital raise through equity dilution.
View raw filing on EDGAR →Holders of convertible notes elected to convert approximately $287.2 million in principal amount of 2.375% Convertible Senior Notes due 2028 into 2,671,056 shares of common stock, resulting in material dilution to existing shareholders. The shares were issued pursuant to the Section 3(a)(9) exemption from registration.
View raw filing on EDGAR →The Company issued 517,000 shares of common stock in exchange for preferred stock held by an existing investor, relying on Section 3(a)(9) of the Securities Act. This is an unregistered equity issuance that increases the common share count materially (517,000 shares) without cash proceeds, representing a dilutive capital transaction typical of small-cap REITs managing preferred stock conversions. The filing explicitly cites Item 3.02 and the Section 3(a)(9) exemption, confirming the dilutive nature of the transaction.
View raw filing on EDGAR →Blue Moon Metals closed a C$35 million non-brokered private placement with The Elmet Group, issuing 3,500,000 units (each comprising one common share and one warrant) at C$10.00 per unit. This is a material dilutive equity issuance raising substantial capital. While the exhibit also discloses a board appointment (William Jacob Homiller), the primary event and headline is the private placement closure, which is the material capital-raising transaction.
View raw filing on EDGAR →The press release announces the closing of a private placement of 4,247,500 units for gross proceeds of $1.7 million. This is a dilutive equity issuance to raise capital, with significant insider participation (1,500,000 FT Units to Chairman Robert Dickinson and associates, and 1,500,000 Units to The Sutton Group Inc., an insider). The proceeds are earmarked for exploration and working capital, and the securities are subject to a statutory hold period, consistent with a private placement structure typical of dilutive issuances at small- and mid-cap mining companies.
View raw filing on EDGAR →This Item 3.02 disclosure describes an unregistered private placement of preferred stock to accredited investors under Regulation D Rule 506(b). The Company issued 210,135 shares of Series 2025 Preferred Stock during the reporting period, raising approximately $2.1 million in aggregate proceeds. As of the filing date, 12.9 million shares of this series were outstanding, indicating substantial ongoing dilution. This is a classic dilutive equity issuance material to investors assessing the registrant's capital structure and ownership.
View raw filing on EDGAR →Stonepeak-Plus Infrastructure Fund LP sold approximately $38.8 million in unregistered limited partnership units to third-party investors on October 1, 2026, pursuant to Section 4(a)(2) and Regulation D exemptions, representing a material private placement that affects the Fund's capital structure and dilution to existing unitholders.
View raw filing on EDGAR →GreenPower converted $1,999,750 in convertible debentures into 2,105 Series B Convertible Preferred Shares and issued 360,572 common shares for accrued interest and dividends. The press release explicitly states this was a strategic decision to improve shareholders' equity and align with Nasdaq's minimum equity requirements. The issuance is material because it involves significant dilution to existing shareholders (360,572 common shares issued plus convertible preferred shares), affects insider ownership materially (Atkinson's stake increased from 27.8% to 29.3% on a non-diluted basis), and directly addresses balance-sheet concerns tied to exchange listing compliance.
View raw filing on EDGAR →Draganfly Inc. closed a registered direct offering of 1,869,159 common shares at US$5.35 per share for gross proceeds of approximately US$10 million pursuant to an effective Form F-10 shelf registration statement, with placement agents Jett Capital Advisors and Northland Securities compensated through warrants to purchase 112,150 common shares at CAD$9.4595 per share.
View raw filing on EDGAR →The filing discloses a private placement of 520,834 shares of common stock at $4.80 per share for approximately $2.5 million in gross proceeds, issued in reliance on Regulation S to a non-U.S. investor (Chan Kai Sang). Items 1.01 and 3.02 explicitly address the unregistered sale of equity securities, which is the hallmark of a dilutive issuance. The shares will bear restrictive legends and the transaction is material to equity holders.
View raw filing on EDGAR →Dynex Capital completed an underwritten public offering of 4,800,000 shares of Series D Preferred Stock (with an additional 720,000 shares optionally available to underwriters), each with a $25.00 liquidation preference and 9.375% cumulative dividend rights. The offering materially dilutes existing shareholders and creates senior claims on assets and earnings.
View raw filing on EDGAR →Largo announces the closing of a registered direct offering of 10.2 million common shares and warrants for US$5.7 million aggregate gross proceeds. This is a material equity issuance that dilutes existing shareholders. The disclosure explicitly notes related-party participation by insiders (ARC Fund IV and Jim Bannantine) and references MI 61-101 exemptions, confirming the transaction's significance. The proceeds are designated for working capital and paying trade creditors, indicating potential financial stress.
View raw filing on EDGAR →Bluerock Acquisition Corp. II completed a $172.5 million IPO on September 24, 2026, with concurrent unregistered private placement of 5,812,500 warrants ($5.8 million) to the Sponsor and underwriter representatives pursuant to Section 4(a)(2) exemption.
View raw filing on EDGAR →Silexion entered into an inducement letter agreement on September 28, 2026, whereby warrant holders exercised existing Series E warrants at a reduced exercise price ($0.2603 vs. $0.65) in exchange for new Series F and G warrants to purchase 6,433,856 additional ordinary shares. The transaction, structured as a private placement under Section 4(a)(2), generates approximately $0.84 million in gross proceeds while creating substantial new dilution through the issuance of 6.4+ million warrant shares.
View raw filing on EDGAR →The Fund sold approximately $79.9 million in unregistered limited partnership units (Class R-S and Class R-I Units) on September 1, 2026, as part of a continuous private offering exempt under Section 4(a)(2) and Regulation D.
View raw filing on EDGAR →The fund issued 17,386.585 Class I common shares for $350,000 as part of a continuous private offering, relying on Section 4(a)(2) and Regulation D/S exemptions.
View raw filing on EDGAR →The 6-K discloses the closing of a warrant exercise window resulting in the issuance of 210,812 ordinary shares at an average price of approximately USD $123.36 per share, increasing share capital by nominal DKK 210,812. This constitutes a dilutive equity issuance that would materially affect shareholder ownership and is reportable under Item 3.02 equivalent disclosure requirements for foreign private issuers.
View raw filing on EDGAR →VistaOne, L.P. sold approximately $24.2 million in unregistered limited partnership units across multiple classes (B, I, R, and S) as of September 1, 2026, pursuant to Section 4(a)(2) and Regulation D exemptions. This private placement represents a dilutive issuance of equity securities to raise capital.
View raw filing on EDGAR →GEN Restaurant Group entered into a Common Stock Purchase Agreement with Roth Principal Investments granting the right to sell up to $25,000,000 of newly issued Class A common stock over 36 months (up to 6,776,399 shares, representing 19.99% of outstanding shares). The agreement includes registration rights and represents a registered direct offering mechanism with significant dilution potential.
View raw filing on EDGAR →T1 Energy Inc. entered into a note purchase agreement on September 28, 2026 to sell $50.0 million in aggregate principal amount of convertible senior notes to a qualified institutional buyer. The convertible notes have an initial conversion price of approximately $4.46 per share (224.0143 shares per $1,000 principal amount), with a maximum of 13,440,860 shares of common stock potentially issuable upon conversion. The company is obligated to register the underlying shares for resale, and the proceeds are intended to finance Phase 1 of G2_Austin.
View raw filing on EDGAR →The filing discloses an unregistered issuance of TGL Shares valued at $500,000 to Mestiz Technology Sdn Bhd in satisfaction of a milestone under a software development agreement (Item 3.02). The company relied on Section 4(a)(2) and Regulation S exemptions from registration. While the primary Item 1.01 addresses a material contract amendment reducing scope and fees, the equity issuance component—particularly the potential for additional dilutive share issuances for the remaining $500,000 in service fees—is the material disclosure triggering Item 3.02 and represents a dilutive capital event.
View raw filing on EDGAR →The 6-K discloses the closing of a private placement to "non-U.S. Persons" pursuant to a securities purchase agreement dated September 24, 2026, which closed on September 28, 2026. This is an unregistered sale of equity securities to foreign investors, a classic dilutive issuance event. The lack of detail on terms and amount does not diminish materiality—private placements to raise capital are material to investors assessing ownership dilution and the company's financing strategy.
View raw filing on EDGAR →